Much conversation and research were going on over a couple of years on a new class of drug- CGRP inhibitors and its potential to prevent and treat a migraine. The US FDA has approved the first treatment- Aimovig (erenumab-aooe) to prevent migraine in adults, belonging to the new class of drug called CGRP inhibitors. Aimovig is developed by Amgen. Read the article to know about Aimovig and developments in the popular area of migraine research- CGRP inhibitors.
Indian Institute of Technology Roorkee (IIT Roorkee) scientists have developed an improved orthopedic implant technology for sustained drug release. Currently, the technology is with the company, Biotech Consortium India Limited (BCIL) for transfer, for the commercialization of the technology.
No new class of antibiotics has been approved over the last fifty years. Currently, there are 10 new classes of antibiotics in the CARB-X portfolio, if any one of them reaches to patients, it would be the first new class of antibiotic to be approved, since 1962. Melinta Therapeutics funding.
Novartis' Kymriah has extended the horizon of personalized cancer treatment. It is the only CAR-T therapy that has received FDA approval for two types of cancer indications- non-Hodgkin lymphoma and B-cell ALL.
First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.
Big pharma players including Novartis, Roche, Pfizer, Sanofi are embracing digital technologies to deliver better to the patients. FDA’S 2018 Strategic Policy Roadmap indicates increasing number of digital health clearances in coming times with revised regulatory processes.
USFDA declined the approval of Pfizer’s Herceptin biosimilar for breast cancer treatment. Pfizer’s biosimilar-PF-05280014 has shown equivalence in the objective response rate with Herceptin in HER2-positive metastatic breast cancer patients in clinical studies.
Within first four months of 2018, seven new drugs are already approved by the FDA for a wide range of diseases including HIV, psoriasis, and rare cancers. 2018 will also see the first ever “game-changing” CRISPR gene editing clinical trial in humans.
UK-based BenevolentAI raised one of the largest fundings in AI pharmaceutical field. The company is significantly disrupting the pharma industry which spends $180 billion in a year on R&D.
Over the next five years, pharma giant, AstraZeneca will invest $90 million in India to improve the overall health outcomes in the country, by promoting innovation, skill development, and quality manufacturing.